Cell therapy (CAR-T) · Kills target cells, directed at mesothelin (MSLN) · developed by MaxCyte
MCY-M11 is an autologous peripheral blood mononuclear cell product transfected with anti-mesothelin chimeric antigen receptor mRNA. Given intraperitoneally, it recognizes, binds, phagocytoses and kills cells expressing mesothelin, a cell surface glycoprotein overexpressed in many epithelial-derived cancers. It is studied in peritoneal mesothelioma, fallopian tube adenocarcinoma, ovarian adenocarcinoma and primary peritoneal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03608618 | Phase 1 | Peritoneal Mesothelioma | Terminated | MXCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenocarcinoma of the OvaryFallopian Tube AdenocarcinomaPeritoneal MesotheliomaPrimary Peritoneal Carcinoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the MXCT page.
See MXCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MXCT catalysts and pipeline →